Skip to main content
Premium Trial:

Request an Annual Quote

Aviva Biosciences Pockets $11.8M in Series B Round

NEW YORK, Sept. 23 - Startup biochip company Aviva Biosciences today said it has secured $11.8 million in the first closing of a series B round of private-equity financing.

 

China Development Industrial Bank, a long-time investor with Aviva, led the round, which brings to $16.8 million invested in Aviva sine 1998. Axon Instruments and Pac-Link Management also took part in the round.

 

Aviva, based in San Diego, said it will us the money to help it launch a biochip it is developing with Axon that will work with that firm's PatchXpress line of ion channel drug-screening systems.

 

Two weeks ago, the company hired former Lynx chief Norrie Russell to be its president and CEO. Russell, who quit Lynx in June, was replaced by Kevin Corcoran, Lynx's vice president of operations and a veteran of Applied Biosystems.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.